Anti-SARS-CoV-2 Neutralizing Antibody ELISA Kit
Product details
Sample type/volume
- Serum: 5 µL
- Plasma: 5 µL
Hands-on time: 40 minutes
Time to result: 1 hour 30 minutes
Homogeneous (without washing): No
Inter-assay CV: <10%
Intra-assay CV: <10%
Instrument: Colorimetric microplate reader
Product size: 96 tests
Content
- Pre-coated 96-well plate
- Control
- SA-HRP conjugate
- Assay buffer concentrate
- wash buffer concentrate
- substrate solution
- stop solution
- Adhesive plate covers
Send conditions: wet ice
Storage: 2-8°C
About this team
The SARS-CoV-2 Neutralizing Ab ELISA is a competitive assay that inversely measures neutralizing antibodies against SARS-CoV-2 Spike RBD in human serum or plasma.
Principle of the method
The ELISA (enzyme-linked immunosorbent assay) for neutralizing human SARS-CoV-2 is designed to measure the neutralizing portion of anti-SARS-CoV-2 antibodies. A receptor-binding domain (RBD) protein is pre-coated onto the wells of the supplied microplate. Samples or positive control are added to the wells and incubated for 30 minutes.
Neutralizing antibodies present in a sample that specifically bind to RBD will block RBD interaction/coverage with added biotinylated ACE2 for 30 minutes after a wash. The SA-HRP signal is indirectly proportional to the amount of specific neutralizing antibodies present.
Destination information
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), also known as 2019-nCoV (2019 Novel Coronavirus), is a virus that causes illnesses ranging from symptoms of the common cold to severe effects including death and respiratory distress. The CoV spike (S) protein plays the most important role in viral attachment, fusion, and entry, and serves as a target for the development of antibodies, entry inhibitors, and vaccines.
Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in the SARS-CoV-2 Spike protein that binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. . The SARS-CoV-2 RBD exhibits a significantly higher binding affinity to the ACE2 receptor than the SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. For research use only. It should not be used in diagnostic procedures. Not for resale without express permission.